Recovery ⏱ Half-life: Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.

ARA-290

ARA-290 (Cibinetide)

Buy from $44.99 →
Half-Life
Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.
Mol. Weight
1257.34 g/mol

What is ARA-290?

ARA-290 (cibinetide) is a pioneering compound that separates the tissue-protective effects of erythropoietin from its blood cell-stimulating properties. It activates a distinct receptor complex that promotes repair without the risks associated with EPO use.

Research Applications

Neuropathy research, tissue protection, anti-inflammatory signaling, sarcoidosis, diabetic complications, and innate repair receptor biology.

Dosage Information (Research Use)

Clinical trial doses: 2-4 mg subcutaneously daily or three times weekly. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.

Reported Observations in Literature

Well-tolerated in clinical trials. No erythropoietic effects. Mild injection site reactions reported.

Key Research References

  • Brines M, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Mol Med. 2015

How ARA-290 Works

ARA-290 activates the Innate Repair Receptor (IRR), a heterodimer of EPO receptor and beta common receptor. Unlike erythropoietin, it does not stimulate erythropoiesis (red blood cell production). Instead, it triggers tissue-protective, anti-inflammatory, and anti-apoptotic signaling pathways.

Research Findings

Clinical trials for sarcoidosis-associated neuropathy and diabetic neuropathy have shown improvement in small nerve fiber density. Represents a new class of tissue-protective compounds.

Dosage & Administration

Clinical trial doses: 2-4 mg subcutaneously daily or three times weekly. Research use only.

Safety & Side Effects

Well-tolerated in clinical trials. No erythropoietic effects. Mild injection site reactions reported.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence pGlu-Glu-Leu-Arg-Gln-Leu-Lys-Trp-Gln-Leu-Leu-NH2
Molecular Weight 1257.34 g/mol
Half-Life Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Brines M, et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med. 2015

Get ARA-290 from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Linaclotide
Recovery
FDA-approved 14-amino acid peptide for IBS-C and chronic constipation that works by activating guanylate cyclase-C receptors in the…
View Profile → Buy at SP →
VIP
Recovery
Endogenous neuropeptide with potent vasodilatory, anti-inflammatory, and immunomodulatory properties across multiple organ systems.
View Profile → Buy at SP →
Vesugen
Recovery
Vascular-targeting tripeptide bioregulator researched for endothelial function and microcirculation support.
View Profile → Buy at SP →